Impact of nursing on hospital patient mortality: a focused review and related policy implications
AE Tourangeau, LA Cranley, L Jeffs - BMJ Quality & Safety, 2006 - qualitysafety.bmj.com
Understanding the determinants of patient mortality can lead to the development of
strategies that reduce mortality and prevent unnecessary death. This paper synthesizes the …
strategies that reduce mortality and prevent unnecessary death. This paper synthesizes the …
[HTML][HTML] Towards understanding the de-adoption of low-value clinical practices: a scoping review
Background Low-value clinical practices are common in healthcare, yet the optimal
approach to de-adopting these practices is unknown. The objective of this study was to …
approach to de-adopting these practices is unknown. The objective of this study was to …
[HTML][HTML] Organizational contextual features that influence the implementation of evidence-based practices across healthcare settings: a systematic integrative review
Background Organizational contextual features have been recognized as important
determinants for implementing evidence-based practices across healthcare settings for over …
determinants for implementing evidence-based practices across healthcare settings for over …
Rational design of cationic lipids for siRNA delivery
SC Semple, A Akinc, J Chen, AP Sandhu, BL Mui… - Nature …, 2010 - nature.com
We adopted a rational approach to design cationic lipids for use in formulations to deliver
small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1, 2-dilinoleyloxy-3 …
small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1, 2-dilinoleyloxy-3 …
RNAi-mediated gene silencing in non-human primates
TS Zimmermann, ACH Lee, A Akinc, B Bramlage… - Nature, 2006 - nature.com
The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing
genes holds great promise for the development of therapeutics directed against targets that …
genes holds great promise for the development of therapeutics directed against targets that …
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
DV Morrissey, JA Lockridge, L Shaw, K Blanchard… - Nature …, 2005 - nature.com
The efficacy of lipid-encapsulated, chemically modified short interfering RNA (siRNA)
targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV …
targeted to hepatitis B virus (HBV) was examined in an in vivo mouse model of HBV …
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA
LB Jeffs, LR Palmer, EG Ambegia, C Giesbrecht… - Pharmaceutical …, 2005 - Springer
No Heading Purpose. A fully scalable and extrusion-free method was developed to prepare
rapidly and reproducibly stabilized plasmid lipid particles (SPLP) for nonviral, systemic gene …
rapidly and reproducibly stabilized plasmid lipid particles (SPLP) for nonviral, systemic gene …
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference
TW Geisbert, LE Hensley, E Kagan… - Journal of Infectious …, 2006 - academic.oup.com
Background Ebola virus (EBOV) infection causes a frequently fatal hemorrhagic fever (HF)
that is refractory to treatment with currently available antiviral therapeutics. RNA interference …
that is refractory to treatment with currently available antiviral therapeutics. RNA interference …
Starting out: A time-lagged study of new graduate nurses' transition to practice
…, A Wolff, S Regan, A Rhéaume-Brüning, L Jeffs… - International journal of …, 2016 - Elsevier
Background As the nursing profession ages, new graduate nurses are an invaluable health
human resource. Objectives The purpose of this study was to investigate factors influencing …
human resource. Objectives The purpose of this study was to investigate factors influencing …
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial.
S Johnston, S Puhalla, D Wheatley, A Ring, P Barry… - 2019 - repository.icr.ac.uk
PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …
breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized …